AMGN

Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. Headquartered in Thousand Oaks, California, the company operates as one of the world's leading independent biotechnology firms with approximately 24,000 employees worldwide. Amgen focuses on areas of high unmet medical need including oncology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. Its portfolio includes blockbuster products such as Enbrel for inflammatory diseases, Neulasta and Neupogen for chemotherapy side effects, Prolia and XGEVA for bone health, and Repatha for cholesterol management. The company generates annual revenues exceeding $26 billion and maintains a significant manufacturing presence across the United States, Europe, and Asia. Amgen operates through a research-driven business model, investing heavily in biotechnology innovation and clinical development. Recent strategic initiatives include the 2023 acquisition of Horizon Therapeutics for approximately $27.8 billion, significantly expanding its rare disease portfolio with products like Tepezza and Krystexxa. The company also focuses on biosimilar development, offering lower-cost alternatives to existing biologic therapies. Amgen markets its products globally through its own commercial organization and partnerships with other pharmaceutical companies, maintaining strong relationships with healthcare providers, payers, and patients across more than 100 countries.